Avalanche Biotechnologies (AAVL) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Avalanche Biotechnologies (AAVL) PT Lowered to $25 at Piper Jaffray on Q2 Results and Wet-AMD Update
August 14, 2015 6:50 AM EDTPiper Jaffray analyst Joshua Schimmer cut his price target on Avalanche Biotechnologies (NASDAQ: AAVL) to $25.00 (from $30.00) following Q2 results and the Wet-AMD updated but maintained an Overweight rating.
Schimmer commented, "After the close, AAVL reported 2Q15 earnings and, not surprisingly, disclosed... More
